Our Mission 

The mission of the Program of Optimal and Safe Prescribing in the EldeRly (PROSPER)​ it to generate high-quality comparative safety and effectiveness real-world evidence for optimal prescribing and deprescribing in older adults based on validated patient phenotyping and detailed treatment effect heterogeneity assessment

What We Do

NIH-Funded National Studies

• A targeted analytical framework to optimize posthospitalization delirium pharmacotherapy in patients with Alzheimer’s disease and related dementias (NIA R01 AG081412, 2023-2027)
• Deprescribing antipsychotics in patients with Alzheimer’s disease and related dementias and behavioral disturbance in skilled nursing facilities (NIA R01 AG081268, 2023-2027)
• Effectiveness and Safety of Transcatheter Left Atrial Appendage Occlusion vs. Anticoagulation in Older Adults with Atrial Fibrillation and Alzheimer's Disease and Related dementias (NIA R01 AG075335, 2022-2026)
• Assessing the effectiveness of oral anticoagulants in patients with atrial fibrillation at high risk of underutilization due to dementia, recurrent falls, or poor anticoagulation quality (NIA RF1 AG063381, 2019-2023)
• Developing dynamic prognostic and risk-stratification models for informing prescribing decisions in older adults with Coronavirus Disease (NIA RF1 AG063381, 2021-2023)
• ​Developing scalable algorithms to incorporate unstructured electronic health records for causal inference based on real-world data (NLM R01 LM013204, 2020-2025)

Selected Research Output

• ​Development of claims-based frailty phenotyping algorithms
  
  • J Gerontol A Biol Sci Med Sci. 2018, PMID: 29244057
    
  • J Gerontol A Biol Sci Med Sci. 2020, PMID: 31566201
    
• Comparative safety and effectiveness in older adults with treatment effect heterogeneity evaluation by frailty and dementia status
  
  • Ann Intern Med 2021, PMID: 34280330
    
  • JAMA Netw Open. 2023, PMID: 36976562
    
  • JAMA Netw Open. 2023, PMID: 36800180
    
• COVID-19 pharmacotherapy in older adults and prognostic algorithm development
  
  • Drugs. 2020, PMID: 33151482
    
  • J Clin Epidemiol. 2022, PMID: 35868493
    
  • Clin Pharmacol Ther 2023, PMID: 37342987
    
  • Pharmacoepidemiol Drug Saf. 2023, PMID: 36464785
    
• Development of claims-based phenotyping models for high-risk features
  
  • J Am Heart Assoc. 2017, PMID: 28982676
    
  • Am J Epidemiol. 2023, PMID: 37650647
    
  • Clin Epidemiol. 2023 PMID: 36919110
    
• Development of high-validity analytic solutions for integrated databases needed for geriatric pharmacoepidemiology
  
  • Epidemiology 2018, PMID: 29283893
    
  • Clin Pharmacol Ther. 2022, PMID: 34424534
    
  • J Am Med Inform Assoc. 2022 PMID: 35357470​